Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01814332 · ClinicalTrials.gov registry record · Phase 2
Analyzing Female Trauma Exposed Responses to a Medication
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT01814332: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT01814332 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 128 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01814332, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
This purpose of this study is to look at the safety of the experimental drug GSK561679 as well as its effects on PTSD symptoms, thinking and memory, startle reaction, stress hormones, and mental health symptoms in comparison to placebo (an inactive substance).
Interventions
- DRUG Placebo
- DRUG GSK561679
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2010-01-01 |
| Est. Completion | 2014-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01814332
The ClinicalTrials.gov registry entry for NCT01814332 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01814332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01814332 about?
NCT01814332 is a clinical study titled "Analyzing Female Trauma Exposed Responses to a Medication". This purpose of this study is to look at the safety of the experimental drug GSK561679 as well as its effects on PTSD symptoms, thinking and memory, startle reaction, stress hormones, and mental health symptoms in comparison to placebo (an inactive substance).
What is the current status of trial NCT01814332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2010-01-01. Estimated completion is 2014-10-31.
What interventions are being tested in trial NCT01814332?
The interventions under investigation include: Placebo (DRUG), GSK561679 (DRUG).
Who is sponsoring clinical trial NCT01814332?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.